Abstract: Described herein are methods for treating inflammation, swelling and secondary damage of the vascular and lymphatic system in a subject, for example of the brain, spinal cord, and lungs; from organ reperfusion, e.g., resulting from endothelial leakage, glycocalyx dysfunction or loss of structural integrity of the glycocalyx.

Abstract: The present application is directed to antimicrobial compositions comprising chitosan polymers of at least two different average molecular weights (Mws), wherein the Mw of each different chitosan polymer is selected to target a different microorganism as well as method of making and using the compositions and product comprising the compositions.

Abstract: An implantable article comprising a dissolvable sponge derived from the mixture of chitosan, a first polysaccharide and a second polysaccharides. The polysaccharides have different number average molecular weight characteristics to enable the control of the mechanical features of the sponge.

Abstract: Described herein are methods of disrupting (e.g., reducing the viscosity of, or dissolving) a preformed biofilm in a subject, the method comprising: administering to the subject an effective amount of a composition comprising a soluble chitosan or derivatized chitosan wherein the soluble chitosan or derivatized chitosan when administered contacts the preformed biofilm, thereby disrupting (e.g., reducing the viscosity of, or dissolving) the preformed biofilm.

Abstract: A biocompatible antimicrobial composition effective against microbial biofilms, including in vivo biofilms containing gram-positive bacteria, can be delivered to and used near the spinal column of vertebrates. Once introduced to an area colonized with a bacterial biofilm, particularly an intervertebral disc, the antimicrobial composition weakens the EPS/ECPS macromolecules of the biofilm, which makes the entire biofilm structure susceptible to being dislodged from the affected area or biosorbed. Additionally or alternatively, certain of the subcomponents of the solute component, as well as perhaps the organic liquid(s) of the solvent component, might lyse microbes, particularly gram-positive bacteria, previously protected by the EPS/ECPS macromolecules. Swelling of and around previously impacted intervertebral discs can be reduced or eliminated, often resulting in appreciable reductions in patient pain levels.

Abstract: The present disclosure relates to methods and products for reducing adhesions. In certain embodiments, the present disclosure provides a method of reducing adhesions in a subject, the method comprising exposing a region in the subject susceptible to formation of an adhesion to an agent having iron chelation and/or antioxidant activity, thereby reducing adhesions in the subject.

Abstract: A tissue adhesive for contacting a tissue site, the tissue adhesive comprising: a mixture of natural polymers; and an activating agent enhancing the adhesive properties of the mixture of natural polymers. And a tissue adhesive for contacting a tissue site, the tissue adhesive comprising: a mixture of natural polymers; and an aqueous solution of a water soluble starch or a water soluble starch derivative which forms a gel with the addition of the mixture of natural polymers.

Abstract: The invention relates to the chitosan polymer derivatives of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Y, X1, X4, R1, R2, and n are defined in the detailed description and claims. The chitosan polymer derivatives of formula I bind to or associate with alpha-4-beta-1 (?4?1) and alpha-V-beta-3 (? V?3) integrin dimers and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing such integrins.

Abstract: The present application is directed to antimicrobial compositions comprising chitosan polymers of at least two different average molecular weights (Mws), wherein the Mw of each different chitosan polymer is selected to target a different microorganism as well as method of making and using the compositions and product comprising the compositions.

Abstract: A degradable and absorbable hemostatic fiber material, a preparation method therefor, and a hemostatic fiber article thereof. The carboxylation degree of the hemostatic fiber material is 10-25%, and the polymerization degree of the hemostatic fiber material is 10-250. The hemostatic fiber material comprises fiber filaments, the linear density of the fiber filament being 0.8-4.5 dtex, and the dry strength of the fiber filament being 10-150 cN/tex. The degradable and absorbable hemostatic fiber material has a higher carboxylation degree and a lower polymerization degree, while the strength and completeness of the fiber filament can be well maintained, such that the hemostatic effect is better and the hemostasis is faster. Further, the hemostatic fiber material can be degraded and absorbed, and thus is safer.

Abstract: Provided herein are compounds, compositions, and methods for modifying mucus, including modifying mucus using nitric oxide-releasing biopolymers (e.g., NO-releasing chitosan oligosaccharides). In some embodiments, a compound, composition, and/or method of the present invention modifies one or more properties of mucus to increase mucus clearance in a subject and/or prevents the growth or kills one or more pathogens present in mucus of a subject.

Abstract: A cleaning and disinfecting composition comprises a long-chain alkyl polyamine, such as dodecyl dipropylene triamine; a long-chain quaternary ammonium salt, such as N,N-didecyl-N,N-dimethylammonium chloride; and a metal carbonate salt, such as potassium carbonate, all in aqueous solution. A sequestering agent, a long-chain alkyl polyethoxylate, an alkanolamine and an anti-corrosive agent may also be present. The composition has a pH of at least 11 when diluted to an in-use concentration, and may be used to clean and disinfect hard surfaces, such as medical, dental and surgical implements, walls, floors, sinks and hard furnishing surfaces, or soft surfaces such as bedding, upholstery or clothing. The composition is effective as a virucide, a sporicide, a bacteriocide, a fungicide, and against yeasts and moulds, without harming the substrate cleansed.

Abstract: A chitosan for use in an antimicrobial treatment of a patient's tissue and a pharmaceutical composition comprising a chitosan for use in an antimicrobial treatment of a patient's tissue. A method of treating a microbial infection, the method comprising the step of administering to a patient an effective amount of a chitosan and an aqueous solution comprising chitosan. A chitosan or a pharmaceutical composition comprising a chitosan for use in an epithelial cell growth stimulating treatment of a patient's tissue. A method of stimulating the growth of epithelial cells the method comprising the step of administering to a patient or to an epithelial cells containing cell culture an effective amount of a chitosan or a pharmaceutical composition comprising chitosan. A tissue dressing material characterized in that it consists of chitosan or a chitosan comprising composition.

Abstract: A dispensing mechanism for delivering a dosage of medicament including a housing having a proximal-distal axis; a plunger rod having a screw thread and configured to advance along the proximal-distal axis relative to the housing; a user-operable push button moveable along the proximal-distal axis relative to the housing; a twist driver threadably engaged with the push button such that movement of the push button towards the distal end of the housing causes rotation of the twist driver about the proximal-distal axis; and a driver engaged with the twist driver such that rotation of the twist driver causes rotation of the driver, the driver also engaged with a portion of the plunger rod such that rotation of the driver causes rotation of the plunger rod, advancing the plunger rod along the proximal-distal axis relative to the housing.

Abstract: The present invention discloses a functionalized hyaluronic acid or a derivative thereof, as well as a process for the preparation thereof, and the use thereof as a biomaterial and as an ingredient in pharmaceutical compositions. The present invention furthermore discloses the use of said functionalized hyaluronic acid or a derivative thereof in the treatment of pathologies ascribable to altered galectin expression.

Abstract: The present invention relates to the unexpected discovery of novel hybrid molecular brush (HMB) polymers and materials that are able to alter their characteristics based on the surrounding solvent properties. In certain embodiments, the HMBs are amphiphilic, comprising a backbone, at least one hydrophilic side-chain, and at least one hydrophobic side-chain. In another aspect, the invention relates to methods of making the HMBs of the invention.

Abstract: The present invention relates generally to therapeutic compositions comprising chitosan-derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.

Abstract: An implantable article comprising a dissolvable sponge derived from a mixture of chitosan, a first cellulosic polysaccharide and a second cellulosic polysaccharide. The cellulosic polysaccharides have different number average molecular weight characteristics to enable the control of the mechanical features of the sponge.

Abstract: The invention relates to lipochitooligosaccharides obtainable from arbuscular mycorrhizal fungi, and which are useful for stimulating arbuscular mycorrhizal symbiosis, and lateral root formation.

Abstract: In one aspect, the present invention includes a haemostat composition that has been washed with an alkali solution to reduce the presence of endotoxins, and which is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.

Abstract: The present invention relates to an injectable homogeneous aqueous solution of chitosan containing, in a physiologically acceptable medium, between 0.1 and 4.5% by weight of a chitosan having a degree of acetylation less than 20% and a weight average molecular mass of between 100,000 and 1,500,000 g/mol, said solution having a pH greater than or equal to 6.2, and advantageously between 6.2 and 7.2, said solution not containing any chitosan having a degree of acetylation greater than 20%, said solution being liquid and homogeneous at ambient temperature.

Abstract: Described herein are methods of treating a subject that has been or will be exposed to radiation, trauma or shock, the method comprising identifying a subject that has been or will be exposed to radiation, and treating the subject with a compound that treats, reduces the severity or delays the onset of sepsis or reduces the likelihood of mortality in a subject upon administration of a therapeutically effective amount the compound to the subject.

Abstract: The disclosure provides, inter alia, polymeric antibiotic compounds such as modified chitosans and methods of use thereof.

Abstract: Aqueous binder compositions with reduced rates of salt precipitation are described. The compositions may include a carbohydrate and a sequestrant for sequestering one or more multivalent ions (e.g., Ca2+, Mg2+, Ba2+, Al3+, Fe2+, Fe3+, etc.). The sequestrant reduces a precipitation rate for the multivalent ions from the aqueous binder composition. Methods of reducing salt precipitation from a binder composition are also described. The methods may include the steps of providing an aqueous binder solution having one or more carbohydrates. They may also include adding a sequestrant for one or more multivalent ions to the aqueous binder solution. The sequestrant reduces a precipitation rate for the multivalent ions from the binder composition.

Abstract: An implantable article comprising a dissolvable sponge derived from the mixture of chitosan, a first polysaccharide and a second polysaccharides. The polysaccharides have different number average molecular weight characteristics to enable the control of the mechanical features of the sponge.

Abstract: A method administers quaternary ammonium anti-cholinergic muscarinic receptor antagonists in combination with acetyl-cholinesterase inhibitors to treat either cognitive impairment or acute delirium. This therapy results in a modification of a cognitive disorder or disease, namely a slow down in the disease progression. In one preferred embodiment, the disease is dementia with Lewy Bodies. New formulations for quaternary ammonium anti-cholinergic muscarinic receptor antagonists are also disclosed.

Abstract: The present invention relates to a pharmaceutical composition for forming a film directly on a wound to accelerate wound healing, a use for the same, a treatment method using the same, and a method for preparing the same. The film-forming composition according to the present invention forms a film directly on the wound to increase the adhesion to the wound. The formed thin hydrophilic film protects the wound surface to prevent infection of the wound surface, retains the physiologically active substance useful for wound healing on the wound surface to promote the wound healing, and allow drugs to be continuously delivered to the wound surface. Therefore, the composition according to the present invention has excellent wound healing effect and has excellent usability as it is not absorbed into clothing, bandage, etc., thus effectively replacing conventional gel or ointment formations for delivering physiologically active substances.

Abstract: The present invention provides a composition comprising (i) chitosan or chitopoly- or chitooligo-saccharides thereof, wherein said chitosan or chitopoly- or chitooligo-saccharides thereof comprise ?-(1-4)-linked D-glucosamine and N-acetyl-D-glucosamine monomers and have a degree of acetylation between 0.05 and 0.20 and an average degree of polymerization ?250 (molecular weight ?42,000 Da), and (ii) a fungicide not containing chitopoly- or chitooligo-saccharides.

Abstract: Biodegradable materials and methods of their manufacture. Certain embodiments of the biodegradable materials include a crustacean shell material, at least one of gelatin, glycerin, and sorbitol, and water, wherein the biodegradable material is characterized in that, when it is exposed to water for an extended period of time, the material at least partially decomposes. Particular embodiments may comprise additional components including sorbitol and glycerin in the case of biodegradable golf ball embodiments, for example.

Abstract: The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).

Abstract: Described herein are methods of treating a subject that has been or will be exposed to radiation, trauma or shock, the method comprising identifying a subject that has been or will be exposed to radiation, and treating the subject with a compound that treats, reduces the severity or delays the onset of sepsis or reduces the likelihood of mortality in a subject upon administration of a therapeutically effective amount the compound to the subject.

Abstract: The invention relates to a multifunctional chitosan grafted surface. Specifically, the invention relates to a chitosan modified with a quaternary ammonium salt (CH-Q) grafted surface that provides various functional properties, including stability (pH 3-9) and unique pH dependent swelling and antibacterial properties.

Abstract: The invention relates to a thermogelling composition comprising a chitosan having N-acetyl-glucosamine units, glucosamine units, and substituted glucosamine units other than the N-acetyl-glucosamine units, said substituted chitosan preferably having a degree of substitution of the glucosamine units ranging from 10 to 50%, expressed as a number of moles of the substituent based on the number of moles of total units, to its preparation and to its applications.

Abstract: Biomaterials are disclosed having unique properties that make it a useful material in adhesives, local drug delivery applications and as filler or bulking material. The biomaterials are strong, safe and easily used as a surgical adhesive. Treated chitosan, modified chitosan or modified and treated chitosan compositions are disclosed displaying strengths suitable for general surgical applications. The materials can be used as a drug delivery vehicle which allows for the localization of the delivered drug as well as a programmable tether which allows for the release of the drug on a timed basis or in response to a physiological state such as the release of proteolytic enzymes. The materials of this invention can also be modified and treated to optimize the retention of water, thereby serving as a useful filler or bulking material.

Abstract: The present invention provides a chemical composition comprised of hydrogen peroxide and a nanoemulsion of long-chained alcohols which in combination these constituents act synergistically boost the kill-time rate of hydrogen peroxide. The peroxide based nanoemulsion formulation for application to skin includes a cosmetically approved peroxide containing compound present in a range to give from about 0.1 to about 4 wt./wt. % released hydrogen peroxide, an organic acid present in a concentration from about 0.01 to about 5 wt./wt. % for adjusting a pH of the formulation in a range from about pH 1 to about pH 4, a long-chained (C9 to C22) aryl and/or alky! alcohol, present in a concentration from about 0.1 to about 20 wt./wt. %, and an emollient present in a concentration from about 0.1 to about 40 wt./wt. %, and an emulsifier present in a concentration from about 0.1 to about 20 wt./wt. % to render the formulation a nanoemulsion.

Abstract: Methods of reducing salt precipitation from a binder composition are described. The methods may include the steps of providing an aqueous binder solution having one or more carbohydrates. They may also include adding a sequestrant for one or more multivalent ions to the aqueous binder solution. The sequestrant reduces a precipitation rate for the multivalent ions from the binder composition. The binder composition may include a polymerization catalyst. Exemplary sequestrants may include polycarboxylic acids or anhydrides. Exemplary sequestrant concentrations may range from about 2 wt. % or less of the aqueous binder solution.

Abstract: The present invention relates to an adhesive composition comprising at least one deacetylated chitosan, an acid and an additional compound.

Abstract: A system and method for controlling bacteria, especially lactic and acetic acid bacteria in the production of ethanol using an organic oxidizing compound in combination with an inorganic oxidizer is provided. Particularly, a mixture of one or more peroxy acids and one or more peroxide compounds is introduced into a fermentation mash so as to inhibit or reduce levels of bacteria that compete with yeast for the fermentation sugars. The peroxy acid and peroxide compounds largely are consumed during the fermentation process and are generally not present in the fermentation by-products, especially recovered distiller's grains.

Abstract: The invention relates to oral and dental hygiene and cleaning agents for reducing restaining of teeth.

Abstract: A method of bio-matching a topical gel, cream or lotion may comprise selecting a vagina of a living body, identifying a secretion of the selected vagina, identifying a composition of the identified secretion, and formulating the topical gel to match the identified composition of the identified secretion.

Abstract: Described herein are methods of treating wounds, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan wherein the soluble or derivatized chitosan when administered contacts the wound, thereby treating the wound.

Abstract: A thin chitosan-based material can be used for biomedical applications. The chitosan has been treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan material. A single or multiple such treatments may be employed. For example, the chitosan material may be irradiated under nitrogen using ?-irradiation, treated under a nitrogen plasma, or both. A thin chitosan material can be readily treated by surface modifying treatments such as irradiating under nitrogen using ?-irradiation, treating under a nitrogen plasma, or both.

Abstract: Aqueous binder compositions with reduced rates of salt precipitation are described. The compositions may include a carbohydrate and a sequestrant for sequestering one or more multivalent ions (e.g., Ca2+, Mg2+, Ba2+, Al3+, Fe2+, Fe3+, etc.). The sequestrant reduces a precipitation rate for the multivalent ions from the aqueous binder composition. Methods of reducing salt precipitation from a binder composition are also described. The methods may include the steps of providing an aqueous binder solution having one or more carbohydrates. They may also include adding a sequestrant for one or more multivalent ions to the aqueous binder solution. The sequestrant reduces a precipitation rate for the multivalent ions from the binder composition.

Abstract: A dry yeast composition which includes 5-adenosyl-L-methionine and a thickener and has excellent storage stability. A thickener is added to a yeast cell concentrate obtained by culturing yeast which has SAMe-producing ability and collecting the cells, and the resultant mixture is dried. Thus, a dry yeast containing a high concentration of 5-adenosyl-L-methionine which has excellent storage stability and excellent bioabsorbability can be easily and profitably produced. It is hence possible to supply a market with a dry yeast composition that contains a high concentration of 5-adenosyl-L-methionine, which is useful as a water-soluble physiologically active substance, and that has excellent storage stability and bioabsorbability.

Abstract: The invention relates to a biodegradable barrier network comprising at least two macromolecular substances, one being anionic and the other one cationic. The invention also relates to applicators and kits comprising components to be used to create said biodegradable barrier network. The invention also relates to the use of said applicator or kit in therapy, such as in medicine, veterinary medicine and horticulture.

Abstract: The method for cleaning dental plaque biofilm from the teeth includes the steps of applying a liquid gellable composition to the teeth, the composition including a positively charged polymer such as chitosan, the liquid composition having a viscosity which results in coverage of substantially all of the exposed areas of the teeth. The liquid composition is then gelled by the addition of a second composition, such as a negatively charged compound. The resulting gelled composition has an adherence to the plaque biofilm which is greater than the adherence between the biofilm and the teeth. The gel layer with the biofilm is peeled off of the teeth, removing the dental plaque.

Abstract: A method of inhibiting postoperative adhesion severity of mammalian tissues. The method includes the application on an operated tissue surface of an effective therapeutic amount of a pharmaceutical composition containing a pharmaceutically acceptable amount of growth factors and sterilized carboxymethylchitosan. A method of inhibiting postoperative adhesion severity that includes the step of applying a composition comprising a growth factor, where the growth factor is used as a modulating factor on mesothelial cell proliferation is also provided.

Abstract: This invention relates to compositions for reducing the absorption or bioavailability of lipids in the gastrointestinal tract, and to methods for the preparation and use of these compositions. The compositions comprise a source of dietary fiber together with a cyclodextrin. The compositions of the invention are suitable for use in the prevention and treatment of obesity or hyperlipidaemia.

Abstract: A wound dressing comprising acylated chitosan fibre. The dressing has a wet strength of 0.3 N/cm or above. The acylated chitosan fibre may have a degree of substitution of 0.10-0.50. The acylated chitosan fibre may preferably have a degree of substitution of 0.20-0.40. The dressing may have an absorbency of 5-25 g/g of a solution containing 8.298 g/l of sodium chloride and 0.368 g/l of calcium chloride dehydrate as measured by BSEN 13726-12002 Part 1 Aspects of Absorbency. The base material of the dressing may be chitosan fibre that has been chemically modified through an acylation process using anhydride and ethanol as the solvent. A method of manufacturing the wound dressing involves reacting chitosan fibre with anhydride and making acylated chitosan felt through a nonwoven process, and through cutting, packing and sterilizing processes.

Abstract: The present invention is directed to compositions containing chitosan, a chitosan derivative or a physiologically acceptable salt thereof, and a short-medium chain dicarboxylic acid amide, or a physiologically acceptable salt thereof, forming a film after application onto the skin, useful for protecting skin of the face and of other affected areas in couperose, rosacea and telangiectasia of the legs.